| VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 2, 2012) - RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB:REPCF) is pleased to report positive results from its interim analysis of six-month post-injection data collected from its first-in-man clinical trial (TS001-2009) designed to test the safety and efficacy of the RepliCel™ technology in men and women with androgenetic alopecia (pattern baldness). The primary protocol objective of the study is to assess the local (at t...continued REPCF |
Wednesday, May 2, 2012
RepliCel Releases Positive Results from the Interim Analysis of Data from its First-in-man TS001-2009 Clinical Trial
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment